• Users Online: 285
  • Print this page
  • Email this page
Year : 2017  |  Volume : 1  |  Issue : 2  |  Page : 34-36

Effect of denosumab in giant cell tumor of bone

Department of Orthopedics, Shri Ramachandra Bhanj Medical College, Cuttack, Odisha, India

Correspondence Address:
Biplabi Sarangadhar Das
Department of Orthopedics, Shri Ramachandra Bhanj Medical College, Cuttack, Odisha
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/oji.oji_15_17

Rights and Permissions

Giant cell tumor (GCT) of bone is a benign tumor with locally aggressive nature. The presence of mononuclear stromal cells and multinucleated giant cells is the microscopic characteristic feature of the GCT. It is an osteoclastic tumor with destruction of tumor is mediated by the receptor activator of nuclear factor kappa-B ligand (RANKL). Denosumab, a RANKL inhibitor, may reduce or eliminate tumor giant cells, the relative content of proliferative, densely cellular tumor stromal cells, replacing with nonproliferative, differentiated woven new bone. We report a case of GCT of the right distal femur in a 20-year-old female, treated with 6 cycles of denosumab as neoadjuvant therapy, which shows consolidation of the lesion and became amenable for extended curettage with phenol cauterization and cementing without going for any radical surgery shown to have very good functional outcome.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded413    
    Comments [Add]    

Recommend this journal